TRDA vs. FULC, TBPH, SLRN, RVNC, PEPG, ESPR, NGNE, LXRX, ANL, and KRRO
Should you be buying Entrada Therapeutics stock or one of its competitors? The main competitors of Entrada Therapeutics include Fulcrum Therapeutics (FULC), Theravance Biopharma (TBPH), Acelyrin (SLRN), Revance Therapeutics (RVNC), PepGen (PEPG), Esperion Therapeutics (ESPR), Neurogene (NGNE), Lexicon Pharmaceuticals (LXRX), Adlai Nortye (ANL), and Korro Bio (KRRO). These companies are all part of the "pharmaceutical preparations" industry.
Fulcrum Therapeutics (NASDAQ:FULC) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, community ranking, dividends, media sentiment, valuation, analyst recommendations and profitability.
Fulcrum Therapeutics presently has a consensus price target of $14.33, indicating a potential upside of 73.74%. Entrada Therapeutics has a consensus price target of $21.00, indicating a potential upside of 44.93%. Given Entrada Therapeutics' higher possible upside, analysts plainly believe Fulcrum Therapeutics is more favorable than Entrada Therapeutics.
In the previous week, Fulcrum Therapeutics had 12 more articles in the media than Entrada Therapeutics. MarketBeat recorded 26 mentions for Fulcrum Therapeutics and 14 mentions for Entrada Therapeutics. Fulcrum Therapeutics' average media sentiment score of 1.11 beat Entrada Therapeutics' score of 0.36 indicating that Entrada Therapeutics is being referred to more favorably in the news media.
Entrada Therapeutics has higher revenue and earnings than Fulcrum Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.
Entrada Therapeutics has a net margin of 14.42% compared to Entrada Therapeutics' net margin of -3,470.05%. Fulcrum Therapeutics' return on equity of 9.73% beat Entrada Therapeutics' return on equity.
89.8% of Fulcrum Therapeutics shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 4.1% of Fulcrum Therapeutics shares are owned by company insiders. Comparatively, 7.6% of Entrada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Fulcrum Therapeutics has a beta of 2.35, indicating that its share price is 135% more volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of -0.38, indicating that its share price is 138% less volatile than the S&P 500.
Fulcrum Therapeutics received 84 more outperform votes than Entrada Therapeutics when rated by MarketBeat users. However, 73.33% of users gave Entrada Therapeutics an outperform vote while only 64.63% of users gave Fulcrum Therapeutics an outperform vote.
Summary
Entrada Therapeutics beats Fulcrum Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Entrada Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TRDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Entrada Therapeutics Competitors List
Related Companies and Tools
